Sung Jun Ma, MD

Sung Jun Ma, MD

Physician

Specialty:Radiation Oncology

Gender: Male

Languages: Korean

Academic Title: Assistant Professor in the College of Medicine

  • About Me

    I am a radiation oncologist who specializes in treating thoracic cancers and head and neck cancers. My goal is always to provide the type of evidence-based, compassionate care that I would want my own loved ones to receive, and each of my patients can rely on me as a support system through their cancer journeys. It’s a privilege to do this work alongside such exceptional colleagues here at the OSUCCC – James, where everyone is committed to offering the most optimal and caring treatment possible. As a member of the Cancer Control Program at The James, my research interests are focused on machine learning in oncology and personalized medicine. I have co-authored over 70 peer-reviewed manuscripts and book chapters. I have had clinical trials funded by groups including the Roswell Park Comprehensive Cancer Center and the National Comprehensive Cancer Network/AstraZeneca. I am a member of the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Korean American Society for Radiation Oncology (KASTRO).

  • Clinical Expertise

    • Skin Cancers
    • Lung Cancers
    • Head and Neck Cancer
  • Where I See Patients

    The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

    The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

    Location Information
  • Education & Training

    Internship - Internal Medicine

    • North Shore University Hospital-Manhasset
      300 Community Dr Ofc Of, Manhasset, NY

    Residency - Radiation Oncology

    • Roswell Park Comprehensive Cancer Center
      Elm And Carlton St, Buffalo, NY

    Graduate

    • State University of New York at Buffalo
      1040 Kimball Tower, Buffalo, NY
  • Academic Office & Contact Information

    Academic Office:

    James Cancer Hospital
    460 W 10th Ave
    Columbus, Ohio 43210-1240

  • Publications

    April 13, 2024

    Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer.

    Gill J, Yendamuri K, Chatterjee U, Yao S, Oladeru OT, Singh AK, Ma SJ

    BMC Cancer

    March 19, 2024

    Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma.

    Gogineni E, Sells BE, Dibs K, Jhawar SR, Haring CT, Limbach AL, Konieczkowski DJ, Ma SJ, Zhu S, Baliga S, Mitchell DL, Grecula JC, Bonomi M, Bhateja P, Old MO, Seim NB, Kang SY, Rocco JW, Chakravarti A, Blakaj DM, Gamez ME

    Cancers (Basel)

    March 5, 2024

    Palliative Quad Shot Radiation Therapy with or without Concurrent Immune Checkpoint Inhibition for Head and Neck Cancer.

    Upadhyay R, Gogineni E, Tocaj G, Ma SJ, Bonomi M, Bhateja P, Konieczkowski DJ, Baliga S, Mitchell DL, Jhawar SR, Zhu S, Grecula JC, Dibs K, Gamez ME, Blakaj DM

    Cancers (Basel)

    December 1, 2023

    Outcomes of definitive local therapy with intensity-modulated radiation therapy in elderly patients ≥70 years with HPV-associated oropharyngeal cancer.

    Baliga S, Yildiz V, Barve R, Farag A, Bhateja P, Gogineni E, Mitchell D, Konieczkowski D, Grecula J, Ma SJ, Zhu S, Liu X, Bonomi M, Blakaj DM

    J Med Virol

    October 2, 2023

    Severe Oral Mucositis After Intensity-Modulated Radiation Therapy for Head and Neck Cancer.

    Iovoli AJ, Turecki L, Qiu ML, Khan M, Smith K, Yu H, Ma SJ, Farrugia MK, Singh AK

    JAMA Netw Open

  • Consulting and Related Relationships

    At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Ma has reported no relationships with companies or entities.